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We wished to determine the effect of of CpG ODN adjuvant on the magnitude and duration of protective
immunity against alcelaphine herpesvirus-1 (AlHV-1) malignant catarrhal fever (MCF), a fatal lymphoproliferative
disease of cattle. Immunity was associated with a mucosal barrier of virus-neutralising antibody. The results showed
that CpG ODN included either with emulsigen adjuvant and attenuated AlHV-1 (atAlHV-1) or alone with atAlHV-1
did not affect the overall protection from clinical disease or duration of immunity achieved using emulsigen and
atAlHV-1. This is in contrast to other similar studies in cattle with BoHV-1 or cattle and pigs with various other
immunogens. In addition to this, several other novel observations were made, not reported previously. Firstly, we
were able to statistically verify that vaccine protection against MCF was associated with virus-neutralising antibodies
(nAbs) in nasal secretions but was not associated with antibodies in blood plasma, nor with total virus-specific
antibody (tAb) titres in either nasal secretions or blood plasma. Furthermore, CpG ODN alone as adjuvant did not
support the generation of virus-neutralising antibodies. Secondly, there was a significant boost in tAb in animals
with MCF comparing titres before and after challenge. This was not seen with protected animals. Finally, there was
a strong IFN-γ response in animals with emulsigen and atAlHV-1 immunisation, as measured by IFN-γ secreting
PBMC in culture (and a lack of IL-4) that was not affected by the inclusion of CpG ODN. This suggests that nAbs at
the oro-nasal-pharyngeal region are important in protection against AlHV-1 MCF.Introduction
Malignant catarrhal fever (MCF) is a usually-fatal lym-
phoproliferative disease of a range of ungulates including
cattle, deer, bison, water buffalo and pigs [1]. It is caused
by members of the Macavirus genus of the subfamily
Gammaherpesvirinae of the Herpesviridae. The best cha-
racterised of these are ovine herpesvirus-2 (OvHV-2) and
alcelaphine herpesvirus-1 (AlHV-1), which are carried
asymptomatically by sheep and wildebeest respectively.
There is no apparent disease in these reservoir hosts,
but when the virus is transmitted to susceptible animals,
MCF often ensues [1]. MCF has a worldwide distribution* Correspondence: david.haig@nottingham.ac.uk
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article, unless otherwise stated.wherever reservoir and susceptible animals co-habit. MCF
is currently a serious problem in several parts of the world
including: Indonesia, where cattle are infected by OvHV-2,
North America, in farmed bison infected by OvHV-2 and
in Eastern and Southern Africa where migrating wilde-
beest transmit AlHV-1 to cattle [1].
MCF in cattle caused by AlHV-1 and OvHV-2 is similar
in clinical presentation with fever, inappetance, ocular
opacity and oral epithelial lesions present in most cases
[1-3]. Histologically, MCF is characterised by lymphocyte
infiltration in multiple tissues, hyperplasia in lymph nodes
and vasculitis most notably in the brain and kidneys [1-3].
The pathogenesis of MCF is an area of active study cur-
rently, and T cells (predominantly CD8+ T cells) accu-
mulating within the tissues are virus-infected [4,5]. These
cells may be responsible for mediating the tissue damageCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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nomes of AlHV-1 and OvHV-2 have been sequenced sho-
wing that they are highly-related but distinct viruses [6,7].
Current control measures for MCF focus on keeping
reservoir and susceptible species apart. This is not always
possible, for example African pastoralists’ cattle that have
been taken from the plains inhabited by wildebeest to up-
land regions to avoid MCF are then susceptible to the ser-
ious diseases of trypanosomosis and East Coast Fever
[8,9]. There have been many attempts in the past to con-
trol MCF by vaccination although these have either failed
or not been reproducible [10-14]. However, we have deve-
loped a vaccine strategy that is successful in preventing
disease in cattle challenged with AlHV-1 by inducing a
mucosal barrier of immunity in the oro-nasal pharyngeal
region of cattle in response to intra-muscular immu-
nisation in the upper neck with attenuated AlHV-1 in
Emulsigen adjuvant [15]. However, the duration of im-
munity is short, peaking at around two months and lasting
up to six months, and a boost immunisation is required to
generate high titre virus-neutralising antibody that corre-
lates with protection [15,16].
The aim of this study was to improve the magnitude and
duration of protective immunity to AlHV-1 by using the
TLR9 agonist unmethylated CpG oligodeoxynucleotide
(CpG ODN) as an adjuvant. The TLRs are microbial pat-
tern recognition receptors on or within epithelial and im-
mune system cells, amongst others, that act as a first line
of defence against infection [17]. TLRs working in concert
or alone can influence the quality and duration of adaptive
immune responses. Furthermore, AlHV-1, along with
many other pathogens, has evidence of CpG suppression
within its genome [6]. CPG ODN has been used suc-
cessfully to enhance the magnitude or quality (Th1/Th2)
of protective immunity to a range of pathogens and its
duration in a variety of different species [18-20] including
cattle [21-25]. Furthermore, there are various CpG ODN
formulations that have different efficacies in any given spe-
cies. The CpG ODN 2007 formulation used in this study
has been proven effective in cattle previously [21-23].
Taking all this together, we have tested unmethylated
CpG ODN as an adjuvant in our MCF vaccine formu-
lation and compared it to emulsigen alone or with both
adjuvants in combination. We used AlHV-1 challenge at
23 weeks after boost immunisation as this had previously
achieved only 50% protection compared to challenge at
7–8 weeks (where > 90% protection has been recorded),
and therefore should allow a measurement of the effect of
CpG ODN on duration of immunity.
Materials and methods
Animals and study design
Clinically healthy and MCF seronegative male Friesian-
Holstein calves, 6–7 months of age were used in theexperiments. All animal experiments were approved by
both the University of Nottingham and the Moredun
Research Institute’s experiments and ethics committees
and complied fully with the Home Office of Great Brit-
ain and Northern Ireland “Animals (Scientific Proce-
dures) Act 1986”. For the study, calves were assigned
randomly to four experimental groups and vaccinated
intramuscularly in the upper neck as described in
Table 1, with atAlHV-1 plus Emulsigen (Group 1, n = 9);
atAlHV-1 plus Emulsigen and CpG (Group 2, n = 9);
atAlHV-1 plus CpG (Group 3, n = 5); and Emulsigen
plus CpG alone (Group 4, n = 5). Numbers were chosen
based on power calculations using data from previous
immunisation experiments [15,16] (see statistical ana-
lysis of data below). Intramuscular immunisation with
atAlHV-1 in Emulsigen (20% v/v, MVP, Omaha, USA)
was used in group 1 and group 2 calves for both prime
and boost immunisations (separated by a period of one
month) and for injection of atALHV-1 and CpGODN
(group 3) and both adjuvants (group 4). Phosphoro-
thioate-stabilized CpG ODN 2007 (TCGTCGTTGT
CGTTTTGTCGTT) provided by Merial (Harlow, UK,
purity > 90%) was included at 1 mg/injection in the
immunisation of group 2 and 3 animals as this had pre-
viously been an effective adjuvant dose in cattle in vari-
ous experimental vaccines [21-23].
All animals were challenged with 10 mL of 103.8
TCID50/mL virulent AlHV-1 given intranasally by spray-
ing 5 mL per nostril at 23 weeks after boost immunisation
(week 27 of the experiment, Table 1 legend). In all expe-
riments, uncoagulated blood and nasal secretions were
collected from all animals immediately prior to primary
immunisation and weekly thereafter as described pre-
viously [15,16]. After virus challenge, animal rectal tem-
peratures were measured daily and clinical scoring was
performed daily after the onset of pyrexia (defined as
rectal temperature > 40 °C). Clinical scoring, based on
temperature, body condition, ocular and nasal lesions, was
used to ensure that all animals were euthanized, with an
overdose of intravenous sodium pentobarbitone, at the
onset of moderate clinical signs [16].
At autopsy, the following tissues were collected: brain,
buccal mucosa, rumen, reticulum, liver, kidney, lung,
prescapular lymph node, mesenteric lymph node (MLN)
and blood. Pieces of each tissue (except blood) were
fixed in (a) 10% formal saline (b) 4% paraformaldehyde
(c) zinc salts fixative [15,16] before processing routinely
and embedding in paraffin wax. Live cell suspensions of
MLN were cryopreserved under liquid nitrogen.
For histological analysis, 4 μm sections of formalin-
fixed tissues were cut, mounted on glass microscope
slides and stained with haematoxylin and eosin. In
addition, total DNA was prepared from blood buffy coat
cells for PCR detection of viral DNA.





NS ab5 NS ab Plas ab6 Plas ab
Pre-chall After chall Pre-chall After chall
Gp 1: Virus + Em
841 99 No MCF lesions NDet 67 79 82 58
920 99 No MCF lesions NDet 24 89 44 60
221 98 No MCF lesions NDet 63 66 42 44
983 98 No MCF lesions NDet 30 50 132 248
001 91 No MCF lesions NDet 195 118 72 109
371 89 No MCF lesions NDet 151 138 79 220
675 89 No MCF lesions NDet 44 70 89 114
635 63 MCF Lesions: Lymphocytic inflammation and
vasculitis. Pneumonia
32.6 35 96 47 449
101 42 Mild MCF lesions: Lymphocytic inflammation and
vasculitis. Pneumonia
32.5 55 220 37 421
Gp 2: Virus + Em +CpG
105 98 No MCF lesions NDet 72 118 89 149
106 98 No MCF lesions NDet 40 66 116 198
706 97 No MCF lesions NDet 85 66 75 73
679 96 No MCF lesions NDet 29 17 81 128
236 91 No MCF lesions NDet 9 24 64 214
162 90 No MCF lesions NDet 64 97 133 218
663* 90 Mild MCF lesions. Lymphocytic inflammation
and vasculitis
33.6 6 234 51 931
400678 41 Mild MCF lesions: Lymphocytic inflammation
and vasculitis. Mild pneumonia
37.5 0 300 60 324
065 35 MCF Lesions: Lymphocytic inflammation and
vasculitis in multiple tissues. Pneumonia
27 0 408 26 299
Gp 3: Virus + CpG
666 90 No MCF lesions NDet 0 25 46 50
021 89 No MCF lesions NDet 19 19 23 68
169 89 No MCF lesions NDet 50 64 85 139
201027 65 Mild MCF lesions. Lymphocytic inflammation and
vasculitis. Pneumonia
27.6 0 40 0 0
273 36 MCF Lesions. Lymphocytic inflammation and
vasculitis. Pneumonia
26.2 0 0 0 220
Gp 4: Adjuvant
658 88 No MCF lesions NDet 0 0 0 0
101027 60 Mild MCF lesions. Lymphocytic inflammation 30.3 0 0 0 0
249 36 Mild MCF lesions. Lymphocytic inflammation and
vasculitis in the brain and liver only
NDet 0 90 0 104
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Table 1 Experimental groups: clinical/histopathology analyses and serology (Continued)
925 36 MCF Lesions. Lymphocytic inflammation and
vasculitis. Pneumonia
24.7 2 74 0 0
986 27 MCF lesions: Lymphocytic vasculitis in
multiple tissues. Pneumonia
30 0 15 0 81
1Em = emulsigen adjuvant, CpG = oligoCpG adjuvant.
2Time from challenge to euthanasia/post-mortem examination.
3Tissues in this analysis were: brain, lung, liver, kidney, prescapular lymph node, alimentary tract epithelium and mesenteric lymph node.
4Viral DNA was assayed in terminal blood samples by qPCR to give a specific and internally-controlled diagnostic test. Data are expressed as Ct values – the cycle
number at which specific amplification was first detected. Moderate/severe MCF usually has values in the range 21–29. NDet = specific amplification of AlHV-1
DNA not detected (but control actin-specific PCR was detected). *This animal had histological evidence of infection.
5Nasal secretion antibody (NS ab) titres pre-challenge and after challenge with virus.
6Plasma antibody (Plas ab) titres pre-challenge and after challenge with virus.
Animals in groups 1, 2 and 3 received the same dose of vaccine (1 mL of 107 TCID50 per mL) for both prime and boost, given intramuscularly and in groups 1 and
2 contained 20%(v/v) Emulsigen. Control animals in group 4 received virus-free culture medium with Emulsigen prepared and administered in the same way.
Animals in all groups were challenged 23 weeks after boost with 10 mL of 103.8 TCID50/mL of virulent AlHV-1 given intranasally. For mild MCF lesions, Viral DNA in
the tissues can be below detection level.
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The strains of AlHV-1 used for vaccination and challenge
were as described previously [15,16]. Briefly, the virulent
C500 strain virus (virAlHV-1) was collected from cultures
of bovine turbinate (BT) cells infected with a lymphoid
cell suspension derived from pooled lymphoid tissue from
rabbits infected with AlHV-1 C500 that had developed
MCF. Infected BT cell cultures were passaged onto fresh
BT cells by a 1:4 split four times at peak cytopathic effect
(approximately weekly) after which virulent virus was har-
vested from culture supernatants and cells following three
rounds of freeze-thaw treatment of the cells. Cell-free
virus supernatant was stored at −80 °C as 1 mL aliquots of
pooled virus in batches and representative aliquots of each
batch were titrated to allow calculation of the appropriate
challenge dose. Titration measured 50% tissue-culture-
infectious dose (TCID50) as described previously [15,16].
The attenuated AlHV-1 C500 strain (atAlHV-1) at
passage > 1000 was used as the source of virus for im-
munisation [15,16]. This cell-free virus was obtained
from BT cell culture supernatants, clarified by centrifu-
gation and stored in batches at −80 °C until required.
Representative aliquots of atAlHV-1 were titrated as
described for virulent AlHV-1. The virus vaccine dose
for both prime and boost comprised 1 mL of 107 TCID50
per mL atAlHV-1 with adjuvant(s) as described above.
Detection of viral DNA
Viral DNA was assayed in pure genomic DNA samples
extracted from blood buffy coat cells by quantitative (q)
PCR as described previously [15,16]. Briefly, ~50 ng of
total DNA was assayed simultaneously for the presence of
AlHV-1 and genomic actin sequences by duplex real-time
PCR analysis. Each 20 μL assay contained 900 μM of each
AlHV-1 forward and reverse primer (AlHV1-F, AlHV1-R)
and 250 μM of the fluorogenic probe FAM-AlHV1;
450 μM of the genomic actin primer (gACT-F: 5’-CAC
CTT CCA GCA GAT GTG GA-3’; gACT-R: 5’-CTA
GAA GCA TTT GCG GTG GAC) and 125 μM of thefluorogenic minor-groove binding (mgb) probe VIC-gACT
(5’-VIC-AGC AAG CAG GAG TAC G-mgb) [26]; and
real-time PCR reagents containing Platinum Taq polyme-
rase and ROX control dye (Invitrogen (Life Technologies),
Paisley, UK). All assays were conducted using standard
conditions on ABI 7000 or 7500 sequence detection sys-
tems (Applied Biosystems (Life technologies), Paisley, UK).
Antibody detection by ELISA and the virus-neutralising
antibody test
The antibody ELISA was used to detect humoral virus-
specific antibody titres in blood plasma samples and nasal
secretions as described previously [16]. An AlHV-1-
negative serum at 1:500 dilution was also included with
each test sample series.
ELISA values (difference between means of positive
and negative antigen wells for each sample dilution)
were used to calculate a relative titre for each test
sample, based on the standard curve produced from the
positive control serum wells on the same plate. Test
samples with ELISA values outside the range found for
the positive control serum were discarded. Standard
pools of NS and plasma were used to prepare serial dilu-
tions (NS 1:20–1:2560 and plasma 1:200–1:6400) that
were used on each test plate. ELISA values from these
standards were used to generate a best fit polynomial
standard curve (y = ax2 + bx + c) for each plate with R2
value greater than 0.98. Relative titres of unknown sam-
ples were calculated from the plate standard curve using
NS samples at a dilution of 1:160 and plasma at 1:500.
The virus neutralisation test was based upon 50% in-
hibition of AlHV-1-induced cytopathic effect (CPE) in
BT cells by dilutions of blood plasma or nasal secretion
fluid as described [15,16]. Assays were carried out in 96
well tissue culture plates with BT cells at greater than
80% confluence. All assays used a high titre bovine anti-
AlHV-1 serum as a standard and included non-specific
toxicity-control wells containing sample and cells with-
out virus.
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An ELISPOT test to quantify IFN-γ release from bovine
PBMCs was carried out using Millipore Multiscreen HTS
IP 0.45 μm ELISPOT plates according to the manufac-
turer’s instructions (Millipore, Watford, UK). Wells were
coated with 100 μL (5 μg/mL) anti bovine-IFN-γ antibody
(clone CC330, AbD Serotec, Oxford, UK) and blocked
with Iscove’s modified Dulbecco’s medium (IMDM) con-
taining 10% FCS. PBMCs were added at 1 × 105 per well in
medium. Viral antigen, previously prepared using 3-[(3-
cholamidopropyl) dimethylammonio]-1-propanesulfonate
(CHAPS) detergent from the C500 strain of AlHV1 was
purified using Amicon Ultra-0.5 μm Centrifugal Filter
Units (Millipore, Oxford, UK) and quantified using a Brad-
ford protein assay (Life Science, Hemel Hemstead, UK)
and added to wells in triplicate at 0.2 μg per well. A com-
bination of 0.1 ng phorbol 12-myristate 13-acetate (PMA,
Sigma-Aldrich, Dorset, UK) and 50 ng Ionomycin (Sigma-
Aldrich, Dorset, UK) per 105 cells in each of two wells
were used to stimulate IFN-γ production as a positive con-
trol. PBMCs in medium comprised the negative control.
Cells were incubated for 72 h at 37 °C in a humidified 5%
CO2 in air tissue culture incubator. Biotinylated anti-
bovine IFN-γ (clone CC302, AbD Serotec, Oxford, UK)
was used as the detection mAb at 4 μg/mL (100 μL/well).
ExtrAvidin Alkaline Phosphatase and Sigma fast BCIP/
NBT substrate (Sigma-Aldrich, Dorset, UK) was utilised
for spot development. Spots were then counted using an
ELISPOT reader (AID GmbH, Oxford Biosystems, Oxford,
UK) and averages taken from antigen exposed triplicates
and negative control triplicates, the difference gives spot
forming cells (SFC).
Supernatant samples (50 μL) collected after 72 h incuba-
tion of the PBMCs with viral antigen were tested using
the Thermo Scientific Bovine IL-4 ELISA Kit (Thermo-
Fisher Scientific, Loughborough, UK. Product# ESS0031).
Pathology and histopathological analyses
Clinical MCF was diagnosed by clinical signs and con-
firmed by histopathological lesions and the detection of
virus DNA in terminal blood samples. In clinically normal
animals, infection was deemed to have occurred if there
was histological evidence of lesions and viral DNA in the
tissues. Clinical signs included fever, nasal and ocular
discharge, conjunctivitis and development of corneal opa-
city. The use of a clinical scoring system ensured that all
animals with MCF were euthanized at a similar stage of
the disease. All surviving animals were euthanized around
13 weeks after pathogenic virus challenge. Clinical scores
and histopathology were recorded. MCF histopathology in
brain, kidney, liver, lung, lymph nodes and alimentary
tract epithelium was examined and scored for the fre-
quency of lesions consistent with MCF. The pathology ofeach case was summarised as MCF (tissues contained sig-
nificant numbers of lesions consistent with a diagnosis of
MCF); mild (a small number of lesions, without extensive
infiltration of lymphocytes, which may or may not be as-
sociated with clinical disease); or negative (no significant
lesions observed). A positive test for AlHV-1 DNA in the
blood on the day of autopsy, in combination with typical
MCF histopathology, was taken as a definitive diagnosis of
either clinical or non-clinical MCF.
Statistical analysis of data
For the survival plot comparisons, a log rank test was
used. For the antibody titre and ELISPOT data compari-
sons, the Mann Whitney test and Student’s t-test were
used. For animal group sizes, a power calculation based
on Fisher’s test was applied [27].
Normally the group size is defined as that which gives
an 80% chance of detecting a difference between treat-
ment groups. We assume (based on experimental data)
that 93% of unvaccinated animals would get MCF (in the
virus challenge group) and that we want to detect protec-
tion at a level of 50% or better. We know from previous
experiments that 6 months after immunisation boost
there will be a 50:50 ratio of survivors to cattle that suc-
cumb to MCF. We estimate that there will be a 80%
chance of detecting a significant difference at a two sided
0.8 significance level. This equates to using at least 8 cattle
for groups 1 and 2. We used 9. For group 3 there is
no published evidence in cattle that immunogen with
CpGODN alone induces a significant protective response
compared to protection positive controls (16–20), so for
this and group 4 animals group sizes were reduced to 5
but still retained statistical power. Previous work had
shown that atALHV-1 alone did not induce an MCF pro-
tective response in cattle after virus challenge (unpub-
lished results).
Results
The effect of CpG ODN adjuvant on survival rates in
vaccinated cattle
Animal details, including time to euthanasia for animals
developing MCF, histopathological findings and detection
of viral DNA in blood samples, are detailed in Table 1,
while survival (protection from clinical MCF) is plotted by
group in Figure 1. Two of nine animals receiving the
standard vaccine formulation (Group 1) developed MCF
after challenge, compared with development of MCF in
four of five animals that received only Emulsigen (Group
4), showing that the vaccination and challenge protocol
employed here was effective. Immunisation using the CpG
ODN adjuvant with atAlHV-1 in the immunisation pro-
tocol (Group 3) did not induce significant protective
immunity against virulent AlHV-1 challenge (Figure 1).
Although 3 of 5 animals in group 3 were protected, this

















Gp1 virus+Em Gp2 virus+Em+CpG
Gp3 virus+CpG Gp4 adjuvant
Survival plot
Figure 1 Survival plot for each of the four groups of cattle.
Kaplan Maier survival plot. Group 1: 9 cattle immunised and boosted
with atAlHV-1 (virus) along with Emulsigen (Em) adjuvant. Group 2: 9
cattle immunised and boosted as in group 1 but including CpG ODN
(CpG) as well as Emulsigen; Group 3: 5 cattle immunised and boosted
with atAlHV-1 (virus) and CpG ODN. Group 4: 5 cattle injected with
adjuvant only. P = 0.02 for group 1 compared to group 4. P = 0.04 for
group 2 compared to group 4. Groups 3 and 4 were not significantly
different (p = 0.24).
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group 4 animals (adjuvant only group receiving virus chal-
lenge). When CpG ODN was used in combination with
emulsigen and AtAlHV-1 (Group 2), there was no in-
crease in survival rate/protection compared to using
emulsigen alone with atAlHV-1 (Group 1). Both group 1
and group 2 cattle were significantly protected (with re-
spect to survival) over the duration of the experiment
when compared to the infection control animals in group
4 (P = 0.02 and P = 0.04, respectively). Postmortem ana-
lysis indicated no evidence of infection in any of the pro-
tected cattle except one group 2 animal (663). Table 1
shows the clinical and histopathological findings of the in-
dividual animals in each group. Clinical presentation for
cattle with MCF was: inappetance, fever (>40 °C for two
or more consecutive days) and ocular and nasal discharge
with ocular opacity in most cases. Histologically, in MCF-
affected animals the lesions consisted of interstitial and/or
perivascular lymphocyte accumulations in non-lymphoid
organs (kidney, liver, lung and brain), and hyperplasia and
some architecture disruption in the lymphoid tissues. In
both types of tissues there was evidence of vasculitis. All
of this is typical of MCF in cattle. Mild MCF presentations
were probably due to euthanasia of the animals at mild to
moderate rather than moderate to severe clinical scores in
accordance with Home Office (UK) ASPA MCF end point
criteria. This could well have been responsible for the low
titres of AlHV-1 DNA in the blood cells in some animals,
for example in group 4 (Table 1). This qPCR analysis ofAlHV-1 DNA in terminal blood samples confirmed the
clinical and histopathological diagnosis of MCF (Table 1).
The survivor of clinical disease in group 2 (663), showed
histological evidence of very mild infection, and was
therefore considered infected but clinically free of disease.
In animals that showed evidence of clinical MCF, lesions
suggestive of bacterial pneumonia were present also in
most of them (8 of 11, Table 1). 663 was not one of these.
Of the 17 animals protected from MCF, there were none
that presented with evidence of pneumonia at autopsy.
Antibody responses to immunisation and virus challenge
Following the primary immunisation, total virus-specific
antibody in both plasma and nasal secretions were low,
but increased after a booster immunisation (Figure 2A,
2B) in groups 1–3. However, group 3 (CpG ODN adjuvant
plus atAlHV-1) animals had lower mean titres than
groups 1 and 2 at most time points and this was sig-
nificant on week 13 (week 9 after boost immunisation) in
both the plasma and nasal secretion samples (Figure 2A,
2B). The peak antibody responses occurred around week
7 (3 weeks after boost) in plasma (Figure 2A) and between
weeks 7 and 13 for groups 1 and 2 animals in nasal
secretions (Figure 2B), after which titres then declined.
Whereas virus-neutralising antibodies were present in the
plasma and nasal secretions of group 1 and group 2 cattle,
these were absent or at very low titre in the group 3 ani-
mals (CpG ODN adjuvant plus atAlHV-1). Titres were
similar in groups 1 and 2 animals, where the group 2 ani-
mals were immunised with atAlHV-1 along with both
emulsigen and CpG ODN adjuvant (Figure 2C, 2D). Total
virus-specific antibody titres in nasal secretions and
plasma were measured after AlHV-1 challenge, and there
was a wide distribution of values, particularly in group 1
and group 2 animals (Figure 2A, 2B).
Antibody responses associated with protection
To determine whether virus specific antibody titres (either
total or virus neutralising antibodies) at around the time
of virus challenge were associated with protection, they
were analysed in vaccinated animals from groups 1 and 2
in which protection from MCF was observed. Titres from
cattle that succumbed to MCF (n = 5) were compared to
those that did not (n = 13). This included the clinically
normal animal in group 2 that had histological evidence of
AlHV-1 infection. Figure 2E shows that, although titre dis-
tributions were large, significantly higher neutralising anti-
body titres in nasal secretions at around the time of virus
challenge (week 27) were associated with animals that
were protected compared to those that succumbed to, or
had evidence of, MCF (P = 0.04). Plasma neutralising anti-
bodies did not correlate with protection, nor did total
virus-specific antibodies in either plasma or nasal secre-
tions (Figure 2E, 2F). To further explore the variation in
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H)  Plasma ELISA pre and post challenge
MCF PROTECTED
P=0.008
Figure 2 (See legend on next page.)
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Figure 2 Virus-specific antibody responses. (A, B) Virus-specific antibody titres in each of the 4 groups of cattle detected by ELISA. Group mean
titres and standard deviation of the mean (SD, bars) are shown for each time point. Arrows show timing of primary (1°) and boost (2°) immunisations
and virus challenge on week 27 (chall). (A) Blood plasma antibody; (B) antibody in nasal secretions (NS). (C, D) Virus neutralising antibody titres in
each of the 4 groups of cattle. These were performed on samples prior to immunisation, at week 7 (3 weeks after booster immunisation) and on
week 26, 1 week prior to virus challenge. Group mean titres and SD are shown for each time point; (C) Neutralising antibody titres in nasal secretions;
(D) Neutralising antibody titres in blood plasma; (E, F) Comparison of total virus-specific antibody titres and virus-neutralising antibody titres in group
1 and 2 at week 26, just prior to virus challenge, in cattle that subsequently developed MCF or were protected (PROT); (E) Comparison in nasal
secretions; (F) Comparison in blood plasma. P values for any significant comparisons are shown in the figures. (G, H) Comparison of total virus-specific
antibody titres on week 26, just prior to virus challenge (pre-chall) and after challenge (taking the highest titre of the various time points after
challenge) in animals that developed clinical MCF compared to those that were protected (PROT). (G) Nasal secretion antibody comparison. (H) Blood
plasma antibody comparison. P values for any significant comparisons are shown in the figures.










































B) IFN-  ELISPOT
P=0.03 P=0.03
  Pre-chall           after chall
Figure 3 IFN-γ secreting PBMC frequencies. (A, B) IFN-γ-secreting
cells expressed as spot-forming cells (SFC) per 106 PBMC. Blood samples
from weeks 0, 2, 7 (3 weeks after booster immunisation), 10, 18 and 26
(1 week prior to virus challenge- Pre-chall) were taken, as well as week
28 and the terminal blood sample prior to euthanasia (Term sample) in
both the MCF and protected animals. A) Analysis of all animals in each
group shown as group means and standard deviation of the mean (SD).
(B) IFN-γ-secreting cell frequencies in individual animals (displayed as a
scatter plot) comparing animals that developed MCF or were protected
(PROT). Significant responses were recorded for the pre-challenge and
after challenge terminal samples only. Note there were 3 terminal blood
PBMC samples with 0 SFC in the MCF group and these do not show on
the log scale used.
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challenge (Figure 2A, 2B), the titres were compared before
(week 26) and after challenge in nasal secretions and
plasma in animals with MCF or those that were protected
(Figure 2G, 2H). The highest titre for each animal sample
was selected from within the various time points after
challenge to make the comparison more robust. There
was a significantly higher mean antibody response in the
nasal secretions and plasma samples from MCF affected
animals in groups 1 and 2 after challenge compared to be-
fore challenge (Titres of 19 ± 24 for nasal secretion anti-
bodies pre-challenge and 252 ± 114 after challenge; titres
of 44 ± 13 for plasma antibodies pre-challenge and 484 ±
257 after challenge) whereas neither nasal secretion titres
nor plasma titres were different before and after challenge
in the protected animals.
The effect of the different adjuvants on IFN-γ- and
interleukin-4 secreting cells
The secretion of the key Th1 and Th2 cytokines,
interferon-γ (IFN-γ) and interleukin-4 (IL-4) respectively,
was assayed in PBMC isolated from uncoagulated blood
collected at a range of time-points during the trial
(Figure 3). Group 1 animals showed the highest group
mean value for IFN-γ for each time point, starting at
3 weeks after immunisation boost (week 7 of the expe-
riment), whereas group 2 animals showed an initial good
response at this time that subsequently declined there-
after up to virus challenge at week 30 of the experiment
(Figure 3A). Group 3 animal PBMCs contained IFN-γ se-
creting cells notably on weeks 7 and 10. Wide variation
was seen in the data for each group at each time point
(Figure 3A), such that there was no significant differences
between groups 1–3 comparisons at any individual time
point. After virus challenge the mean frequency of IFN-γ-
secreting cells in PBMC increased in groups 1 and 3 ani-
mals compared to week 26 pre-challenge levels, although
this was not significant. A comparison of IFN-γ-secreting
cells in blood samples taken just prior to virus challenge
(week 26) and in the terminal blood samples prior to
euthanasia indicated that animals protected against MCF
exhibited significantly higher numbers of cells producing
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those that succumbed to MCF (Figure 3B, P = 0.03 for an
analysis on each day).
IL-4 was not detected in any of the samples (results
not shown).
Discussion
In this study, we wished to determine whether the TLR9
agonist CpG ODN used with atAlHV-1 alone or in com-
bination with Emulsigen and atAlHV-1 could improve the
magnitude and duration of protective immunity afforded
by our vaccine against AlHV-1 associated MCF. We show
that the inclusion of CpGODN as an adjuvant was not
effective in this regard, nor did it affect the degree of
disease protection obtained with atALHV-1 and emul-
sigen alone. Previous studies using a similar immunisation
regime involving CpGODN in BoHV-1 immunisation
[22,23] had shown that CpG ODN included with emul-
sigen increased the duration of immunity and also en-
hanced a IFN-γ response in T cells (Th1-like response) as
evidenced by increased cellular production of IFN-γ com-
pared to Th2 cytokine responses (IL-4). Furthermore,
in other studies where CpG ODN was included with a
“traditional” well-established adjuvant (e.g. montanide)
and either nominal antigen (hen egg lysozyme [25])
Mycoplasma bovis [21] or foot and mouth disease virus
(FMDV) [24]) an increase in the duration of immunity
and also an enhanced Th1 response as evidenced by
increased cellular production of IFN-γ compared to Th2
cytokine responses was recorded. In contrast, in this
study, the CpG ODN used in atAlHV-1 vaccine formula-
tions on its own or in combinations with Emulsigen as an
adjuvant did not significantly alter the period of protective
immunity or enhance the magnitude of the immune
response parameters measured over that achieved with
Emulsigen alone with atAlHV-1 (Figure 1, Table 1,
Figure 2). Total virus-specific antibody titres and virus-
neutralising antibody titres in blood plasma and nasal se-
cretions were not enhanced by the inclusion of CpG
ODN, and neither was the frequency of IFN-γ expressing
blood cells restimulated in vitro. IL-4 secretion by blood
leukocytes was not detected. The reason for the difference
between our study and the others may be that the com-
bination of atALHV-1 with emulsigen is already maxi-
mally efficient at inducing an IFN-γ response and this
cannot be improved upon by the inclusion of CPGODN,
leading to an increased duration of immunity (assuming
there is a correlation). In aged pigs given pseudorabies
vaccine, a suboptimal Th1 response was restored when
CpGODN was used as an adjuvant (27). Comparing our
study with the BoHV-1 subunit ones [22,23], which follow
a very similar immunisation regime, would indicate that
the principal difference is in the nature of the immunising
antigens. AtALHV-1 virions were used in our studycompared to BoHV-1 subunit proteins in the other studies
[22,23]. This is worthy of further study.
In this study, the use of CPG ODN on its own with
atAlHV-1 was not effective in inducing protection to
clinical MCF, and this is also the case in the other stud-
ies in cattle where CpGODN was used as an adjuvant on
its own [21-25] and in pigs with FMDV vaccination [28].
We have previously shown that the atAlHV-1 remains
viable when mixed with Emulsigen adjuvant but no evi-
dence of virus replication or persistence after prime and
boost vaccination has ever been detected [15], and un-
published result.
In spite of the lack of vaccine improvement by CpG
ODN, which in itself is an important result, there were
several other novel, aspects to the study. We have quan-
titatively-confirmed our previous observation [16] that
virus neutralising antibody responses in nasal secretions
just prior to virus challenge correlated with protection
(P = 0.04, Figure 2E, 2F) in group 1 and group 2 animals.
Neither plasma antibody (total virus-specific or virus-
neutralising antibody) correlated with protection, nor did
total virus-specific antibody in nasal secretions (Figure 2E,
2F). This supports the hypothesis that a mucosal barrier
with neutralising antibody is important to inhibit AlHV-1
infection to a point where disease is prevented. Notably,
despite 3 of 5 animals being protected in group 3 (CpG-
ODN plus atALHV-1 immunised animals), CpG-ODN as
adjuvant on its own induced very low or no virus-neutra-
lising antibody responses (Figure 2C, 2D). However, these
animals exhibited moderate total virus-specific antibody re-
sponses in both plasma or nasal secretions (Figure 2A, 2B).
This suggests that immune mechanisms other than
virus-neutralising antibody may influence protection from
virAlHV challenge. Unfortunately, despite thorough inves-
tigation of methods that could be used for the detection of
cytotoxic T cells (CTLs) in these experiments, no CTL
assay that we developed was robust enough (reproduci-
bility, sensitivity) to address this aspect of immune re-
sponsiveness in this experiment.
After challenge with virus, animals that developed MCF
showed a significant increase in virus-specific antibody
titres (before succumbing to disease) compared to levels
prior to challenge, whereas those that were protected did
not (Figure 2G, 2H). This increase was more pronounced
in the plasma of MCF-affected animals than in their nasal
secretions (Titres of 19 ± 24 for nasal secretion antibodies
pre-challenge and 252 ± 114 after challenge; titres of 44 ±
13 for plasma antibodies pre-challenge and 484 ± 257 after
challenge). This further reinforces the view that protected
animals prevent virus from entering the host by the oro-
nasal route and thereby stimulating a systemic antibody
response. Furthermore, the more pronounced effect of
challenge on circulating antibody levels in MCF animals
supports this, as virus establishing systemically would be
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tres. In spite of stimulating a high titre antibody response,
all but one of the animals succumbed to disease, so this
response is not protective. In the clinically-normal animal
that had evidence of infection post-mortem, there was also
evidence of an antibody response indicating a response to
infection (Table 1). The fact that this animal survived be-
yond the time that all others had succumbed to MCF
might indicate that whereas vaccination protects against
disease it does not protect against infection in all cases, or
vaccination induced a delay in onset. In previous experi-
ments testing our vaccine, animals succumbed to MCF
within the time to euthanasia set in this study, with one
group of survivors showing no signs of MCF up to a year
after challenge (15,16).
The frequency of IFN-γ producing cells (after in vitro
stimulation of PBMC in culture with virus antigen) was
high in group 1 and group 2 animals, indicating a good re-
sponse to immunisation and boost with emulsigen with
atAlHV-1 (Figure 3A) or emulsigen and CpG ODN with
atAlHV-1. This was confirmed by the association of a
significantly-higher frequency of IFN-γ secreting cells in
protected animals compared to those that succumbed to
MCF in groups 1 and 2, both in week 26 pre-challenge
samples and in PBMC samples taken prior to euthanasia
(Figure 3B). The inclusion of CpG ODN with emulsigen
in the vaccine formulation (group 2 animals) did not
enhance the response compared to that supported by
emulsigen alone (Figure 3A), but with CpG ODN on its
own with atAlHV-1 (group 3) there was a small effect on
IFN-γ secreting cells. The lack of an augmentation of
IFN-γ producing cells by CpG ODN in group 2 animals is
different to other studies, where the adjuvant had an effect
in this respect (21–24).
IL-4 was not detected in PBMC cultures. IL-4 is a key
indicator of Th2 responses but levels recorded in cattle
are usually low in the absence of a strong Th2 response
[29]. The lack of detection herein does not rule out Th2
involvement, but the frequency of IFN-γ expressing cells
does suggest a good Th1 response.
Finally, an interesting observation is that animals with
clinical MCF also showed evidence of bacterial pneumonia
at autopsy, whereas animals with no evidence of clinical
disease did not exhibit the pneumonia. This raises the pos-
sibility that MCF might predispose cattle to pneumonia.
Conclusion
In conclusion, CpG ODN did not alter the quality, magni-
tude or duration of immunity in cattle immunised against
AlHV-1 MCF when used in combination with emulsigen
which is in contrast to other studies in cattle showing
improved immunity in immunisation regimes to other
pathogens [21-24]. It may be that further adjuvants are ne-
cessary, such as the use of host defense peptide andphosphosphazine in combination with CpGODN [25]. The
production of a mucosal barrier of virus-neutralising anti-
body at the oro-nasal transmission entry site of AlHV-1 to
prevent infection and the establishment of disease is
successful in our prime-boost immunisation strategy, but
peaks at approximately two months after booster im-
munisation. Mucosal immune responses are tightly regu-
lated and finding a way of improving the magnitude and
duration of protection against AlHV-1 MCF remains a
challenge.
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